论文部分内容阅读
目的探讨子宫内膜癌中Maspin蛋白、u PA蛋白及雌激素受体(ER)、孕激素受体(PR)间表达的相关性及临床意义。方法对2004年6月至2014年6月病理科存档的蜡块,子宫内膜癌50例、不典型增生的子宫内膜50例及正常增殖期子宫内膜30例,采用免疫组化SP法,检测Maspin蛋白、u PA蛋白、ER、PR的表达情况,结合临床病理特征分析4种蛋白间表达的相关性。结果 Maspin蛋白、ER、PR在增殖期子宫内膜,不典型增生的子宫内膜,子宫内膜癌中阳性表达率逐渐降低,且组间比较有统计学意义(P<0.05),而u PA的阳性表达率逐渐升高(P<0.05)。Maspin、u PA、ER、PR的阳性表达率在手术病理分期、肌层浸润深度及有无淋巴结转移组中的差异均有统计学意义(P<0.05)。Maspin和ER、PR的表达呈一致性,Maspin与u PA呈负相关(r=-0.341,P<0.05),u PA和ER呈负相关(r=-0.293,P<0.05)。结论 ER、PR的减少,Maspin蛋白表达的缺失,伴随u PA蛋白表达上调,四者均参与了子宫内膜癌的发生、发展、浸润等过程,有可能成为判断子宫内膜癌治疗及预后的指标。
Objective To investigate the correlation and clinical significance of Maspin protein, uPA protein, estrogen receptor (ER) and progesterone receptor (PR) expression in endometrial carcinoma. Methods From June 2004 to June 2014, 50 cases of endometrial carcinoma, 50 cases of atypical hyperplasia endometrium and 30 cases of normal proliferative endometrium were enrolled in the pathology department. The immunohistochemical SP method The expressions of Maspin protein, uPA protein, ER and PR were detected. The correlations among the four proteins were analyzed by clinicopathological features. Results The positive expression rates of Maspin protein, ER and PR in proliferative endometrium, atypical hyperplasia endometrium and endometrial carcinoma decreased gradually with statistical significance (P <0.05) and uPA The positive expression rate gradually increased (P <0.05). The positive expression rates of Maspin, u PA, ER and PR in the pathological stage, the depth of myometrial invasion and the presence or absence of lymph node metastasis were all significantly different (P <0.05). Maspin and ER, PR expression was consistent, Maspin and u PA was negatively correlated (r = -0.341, P <0.05), u PA and ER was negatively correlated (r = -0.293, P <0.05). Conclusions The decrease of ER and PR, the loss of Maspin protein expression and the up-regulation of u PA protein in the endometrial carcinoma are all involved in the occurrence, development and infiltration of endometrial carcinoma, which may be the way to judge the treatment and prognosis of endometrial carcinoma index.